Skip to content

NYSE · large · thesis board

NVS Novartis

BTK inhibitor (remibrutinib)

View race

Thesis

Editorial summary — not a primary filing

Remibrutinib and broader immunology; cash and commercial reach support the race.

Next gate

2027-02-20EstimatedPh3 readout

Phase 3 update

191 days · Estimated: Estimated window

Survive-to-Event

ok

Cash covers the next gate with ~21 months spare (curated estimate).

Unverified estimate — not from a live SEC parse

Cash runway (~836d)100%
Days to gate (191d)23%
Show math

$11.0B cash ÷ $400M/mo burn ≈ 836 days. Source: curated SEC quarter figures.

Cash $11.0B as of 2026-03-31 (SEC)

Pipeline spine

  1. Preclinical
  2. Ph1
  3. Ph2
  4. Ph3
  5. Filed
  6. Approved

Rivals in this race

Open race →
SNYFiledokRHHBYPh3okPRTAPh2ok

Risks

  • Crowded BTK class
  • Differentiation
  • Execution
  • Policy

Source trail

  1. SECCash from latest reported quarter (curated)as of 2026-03-31
  2. ClinicalTrials.govNCT05147220as of 2026-07-01
  3. CompanyIR / press disclosuresas of 2026-07-01